Completed PHASE3 INTERVENTIONAL 2-arm NCT02471963

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Sponsor: University of Erlangen-Nürnberg Medical School

Conditions Diabetes Mellitus Type 2

Interventions Empagliflozin Placebo

Updated 5 times since 2017 Last updated: May 9, 2018 Started: Dec 31, 2014 Primary completion: Nov 30, 2015 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02471963, this PHASE3 trial focuses on Diabetes Mellitus Type 2 and remains completed. Sponsored by University of Erlangen-Nürnberg Medical School, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Erlangen-Nürnberg Medical School

Data source: University of Erlangen-Nürnberg Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Erlangen, Germany